736 related articles for article (PubMed ID: 11469882)
1. Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients?
Kymionis GD; Dimitrakakis CE; Konstadoulakis MM; Arzimanoglou I; Leandros E; Chalkiadakis G; Keramopoulos A; Michalas S
J Surg Res; 2001 Aug; 99(2):161-8. PubMed ID: 11469882
[TBL] [Abstract][Full Text] [Related]
2. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
4. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
Bottini A; Berruti A; Bersiga A; Brizzi MP; Brunelli A; Gorzegno G; DiMarco B; Aguggini S; Bolsi G; Cirillo F; Filippini L; Betri E; Bertoli G; Alquati P; Dogliotti L
Clin Cancer Res; 2000 Jul; 6(7):2751-8. PubMed ID: 10914720
[TBL] [Abstract][Full Text] [Related]
5. The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer.
Sjöström J; Blomqvist C; von Boguslawski K; Bengtsson NO; Mjaaland I; Malmström P; Ostenstadt B; Wist E; Valvere V; Takayama S; Reed JC; Saksela E
Clin Cancer Res; 2002 Mar; 8(3):811-6. PubMed ID: 11895913
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
[TBL] [Abstract][Full Text] [Related]
8. Immunofluorometric study of Bcl-2 and Bax expression in clinical fresh tumor samples from breast cancer patients.
Martínez-Arribas F; Núñez-Villar MJ; Lucas AR; Sánchez J; Tejerina A; Schneider J
Anticancer Res; 2003; 23(1B):565-8. PubMed ID: 12680147
[TBL] [Abstract][Full Text] [Related]
9. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
[TBL] [Abstract][Full Text] [Related]
10. bcl-2 and apoptosis in lymph node positive breast carcinoma.
Berardo MD; Elledge RM; de Moor C; Clark GM; Osborne CK; Allred DC
Cancer; 1998 Apr; 82(7):1296-302. PubMed ID: 9529021
[TBL] [Abstract][Full Text] [Related]
11. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
[TBL] [Abstract][Full Text] [Related]
12. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
13. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.
Spataro VJ; Litman H; Viale G; Maffini F; Masullo M; Golouh R; Martinez-Tello FJ; Grigolato P; Shilkin KB; Gusterson BA; Castiglione-Gertsch M; Price K; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Collins J; Gelber RD; Coates AS; Goldhirsch A;
Cancer; 2003 Apr; 97(7):1591-600. PubMed ID: 12655514
[TBL] [Abstract][Full Text] [Related]
14. Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2.
Schuyer M; van der Burg ME; Henzen-Logmans SC; Fieret JH; Klijn JG; Look MP; Foekens JA; Stoter G; Berns EM
Br J Cancer; 2001 Nov; 85(9):1359-67. PubMed ID: 11720475
[TBL] [Abstract][Full Text] [Related]
15. The effect of chemotherapy on Ki-67, Bcl-2 and Bak expression in primary tumors and lymph node metastases of breast cancer.
Koda M; Sulkowska M; Kanczuga-Koda L; Tomaszewski J; Kucharczuk W; Lesniewicz T; Cymek S; Sulkowski S
Oncol Rep; 2007 Jul; 18(1):113-9. PubMed ID: 17549355
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of Bcl-2 in invasive breast cancer receiving chemotherapy and endocrine therapy.
Yang Q; Sakurai T; Yoshimura G; Suzuma T; Umemura T; Nakamura M; Nakamura Y; Mori I; Kakudo K
Oncol Rep; 2003; 10(1):121-5. PubMed ID: 12469156
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of apoptosis associated genes bax and bcl-2 in ovarian cancer.
Marx D; Binder C; Meden H; Lenthe T; Ziemek T; Hiddemann T; Kuhn W; Schauer A
Anticancer Res; 1997; 17(3C):2233-40. PubMed ID: 9216694
[TBL] [Abstract][Full Text] [Related]
18. Image cytometric bcl-2:bax and bcl-2:bcl-x ratios in invasive breast carcinoma: correlation with prognosis.
Schiller AB; Clark WS; Cotsonis G; Lawson D; DeRose PB; Cohen C
Cytometry; 2002 Aug; 50(4):203-9. PubMed ID: 12210599
[TBL] [Abstract][Full Text] [Related]
19. The importance of prognostic factors in premenopausal women with breast cancer.
Finek J; Holubec L; Topolcan O; Elgrova L; Skalova A; Pecen L
Anticancer Res; 2007; 27(4A):1893-6. PubMed ID: 17649790
[TBL] [Abstract][Full Text] [Related]
20. The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer.
Buchholz TA; Garg AK; Chakravarti N; Aggarwal BB; Esteva FJ; Kuerer HM; Singletary SE; Hortobagyi GN; Pusztai L; Cristofanilli M; Sahin AA
Clin Cancer Res; 2005 Dec; 11(23):8398-402. PubMed ID: 16322301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
